Peptide Receptor Radionuclide Therapy with 177Lu-octreotate in Patients with Foregut Carcinoid Tumours of Bronchial, Gastric and Thymic Origin

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2007 Jan 30

PMID 17260141

Citations 35

Authors

Martijn Van Essen

Eric P Krenning

Willem H Bakker

Wouter W de Herder

Maarten O van Aken

Dik J Kwekkeboom

Affiliations

Soon will be listed here.

Abstract

Purpose: Foregut carcinoid tumours have a different embryological origin than other gastroenteropancreatic neuroendocrine tumours (GEP NETs). In the total group of GEP NETs (n = 131), treatment with (177)Lu-octreotate resulted in tumour remission in 47% of patients, with a median time to progression (TTP) of >36 months. As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin.

Methods: Nine patients with bronchial, five with gastric and two with thymic carcinoids were treated. All patients had metastasised disease. The intended cumulative dose of (177)Lu-octreotate was 22.2-29.6 GBq. Southwest Oncology Group criteria were used for response evaluation.

Results: Bronchial carcinoids: Five patients had partial remission, one had minor response (MR, tumour size reduction: > or =25%, <50%), two had stable disease (SD) and one had progressive disease (PD). Median TTP was 31 months. Gastric carcinoids: One patient had complete remission, one had MR and two had SD, including one with PD at baseline. One patient developed PD. Thymic carcinoids: One patient had SD. In the other patient, disease remained progressive. All patients: Overall remission rate was 50%, including MR.

Conclusion: (177)Lu-octreotate treatment can be effective in patients with bronchial and gastric carcinoids. Its role in thymic carcinoids cannot be determined yet because of the limited number of patients. The overall remission rate of 50% in patients with the studied foregut carcinoids is comparable to that in the total group of GEP NETs.

Citing Articles

Update on thymic epithelial tumors: a narrative review.

Cabezon-Gutierrez L, Pacheco-Barcia V, Carrasco-Valero F, Palka-Kotlowska M, Custodio-Cabello S, Khosravi-Shahi P Mediastinum. 2024; 8:33.

PMID: 38881809 PMC: 11176988. DOI: 10.21037/med-23-47.

Management of Gastric Neuroendocrine Tumors: A Review.

Sok C, Ajay P, Tsagkalidis V, Kooby D, Shah M Ann Surg Oncol. 2023; 31(3):1509-1518.

PMID: 38062290 PMC: 10922891. DOI: 10.1245/s10434-023-14712-9.

Lung Carcinoids: A Comprehensive Review for Clinicians.

Granberg D, Juhlin C, Falhammar H, Hedayati E Cancers (Basel). 2023; 15(22).

PMID: 38001701 PMC: 10670505. DOI: 10.3390/cancers15225440.

Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of Tb into the Clinic.

Favaretto C, Grundler P, Talip Z, Landolt S, Sepini L, Koster U J Nucl Med. 2023; 64(7):1138-1144.

PMID: 37201956 PMC: 10315698. DOI: 10.2967/jnumed.122.265268.

Efficacy and Safety of [Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic....

Hertelendi M, Belguenani O, Cherfi A, Folitar I, Kollar G, Polack B Biomedicines. 2023; 11(4).

PMID: 37189646 PMC: 10135775. DOI: 10.3390/biomedicines11041024.

References

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

Kwekkeboom D, Mueller-Brand J, Paganelli G, Anthony L, Pauwels S, Kvols L . Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005; 46 Suppl 1:62S-6S. View

Green S, Weiss G . Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992; 10(4):239-53. DOI: 10.1007/BF00944177. View

Modlin I, Lye K, Kidd M . A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97(4):934-59. DOI: 10.1002/cncr.11105. View

Soga J, Yakuwa Y, Osaka M . Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999; 5(5):285-92. View

Mulkeen A, Cha C . Gastric carcinoid. Curr Opin Oncol. 2004; 17(1):1-6. DOI: 10.1097/01.cco.0000147899.04701.c6. View

Kwekkeboom D, Teunissen J, Bakker W, Kooij P, de Herder W, Feelders R . Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12):2754-62. DOI: 10.1200/JCO.2005.08.066. View

Waldherr C, Pless M, Maecke H, Haldemann A, Mueller-Brand J . The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12(7):941-5. DOI: 10.1023/a:1011160913619. View

Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M . Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol. 2000; 9(1):47-57. DOI: 10.1097/00019606-200003000-00008. View

10.

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

11.

Teunissen J, Kwekkeboom D, de Jong M, Esser J, Valkema R, Krenning E . Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol. 2005; 19(4):595-616. DOI: 10.1016/j.bpg.2005.04.001. View

12.

Crocetti E, Paci E . Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. Eur J Cancer Prev. 2003; 12(3):191-4. DOI: 10.1097/00008469-200306000-00004. View

13.

Anthony L, Woltering E, Espenan G, Cronin M, Maloney T, McCarthy K . Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002; 32(2):123-32. DOI: 10.1053/snuc.2002.31769. View

14.

Rindi G, Capella C, Solcia E . Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med. 2000; 44(1):13-21. View

15.

Williams E, Sandler M . The classification of carcinoid tum ours. Lancet. 1963; 1(7275):238-9. DOI: 10.1016/s0140-6736(63)90951-6. View

16.

Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche E . Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002; 43(5):610-6. View

17.

Kwekkeboom D, Bakker W, Kooij P, Konijnenberg M, Srinivasan A, Erion J . [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28(9):1319-25. DOI: 10.1007/s002590100574. View

18.

Soga J, Yakuwa Y . Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg. 1999; 5(4):211-9. View

19.

Reubi J, Waser B, Schaer J, Laissue J . Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001; 28(7):836-46. DOI: 10.1007/s002590100541. View

20.

Brambilla E, Travis W, Colby T, Corrin B, Shimosato Y . The new World Health Organization classification of lung tumours. Eur Respir J. 2002; 18(6):1059-68. DOI: 10.1183/09031936.01.00275301. View